tbuckley/cabot-search huggingface dataset:
MDM2 Antagonists Activate p53 and Synergize with Genotoxic Drugs To Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells but Not in T Cells.
Authors: Joan Gil, Llorenç Coll-Mulet, Daniel Iglesias-Serret, Antonio F. Santidrián, Esther Castaño, Clara Campàs, Montserrat Barragán, Ana M. Cosialls, Mercé De Frias, Alberto Fernández de Sevilla, Alicia Domingo, Lyubomir T. Vassilev, Gabriel Pons
Journal: Blood (2005)
Transfusion of Red Blood Cells
Authors: Jason Alexander, Adam S. Cifu
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
Authors: Jatin J. Shah, Rafat Abonour, Brian G M Durie, Jayesh Mehta, Mohit Narang, Howard Terebelo, Cristina J Gasparetto, Sachdev P. Thomas, Kathleen Toomey, James W Hardin, Shankar Srinivasan, Rosanna J. Ricafort, Yasir Nagarwala, Robert M. Rifkin
Journal: Blood (2014)
Validation of Positive Effect of Posaconazole Prophylaxis During Induction Chemotherapy in AML: Study of Invasive Aspergillosis Incidence and of Risk Factors On Short and Long-Term Survival.
Authors: Mauricette Michallet, Mohamad Sobh, Stéphane Morisset, Giovanna Cannas, Franck Emmanuel Nicolini, Sophie Ducastelle, Emmanuelle Nicolas-Virelizier, Fiorenza Barraco, Youcef Chelghoum, Samira Kraghel, Nathalie Tedone, Mohamed El Hamri, Hélène Labussière, Xavier Thomas, Anne-Lise Bienvenu, Frédérique De Monbrison, Stéphane Picot, Marie-Christine Nicoll, Philippe Vanhems
Journal: Blood (2009)
TCT-681 Aggressive oversizing of balloon-expandable transcatheter aortic valve replacement: predictor of para valvular leak with severe aortic valvar complex calcification
Authors: Yoshio Maeno, Yoshio Kazuno, Yigal Abramowitz, Hiroyuki Kawamori, Nobuyuki Takahashi, Mohammad Kashif, Tarun Chakravarty, Mamoo Nakamura, Wen Cheng, Raj Makkar, Hasan Jilaihawi
Journal: Journal of the American College of Cardiology (2015)
Cancer-related maternal mortality.
Authors: S. A. Harvey, J. Burlingame, J. Davis, K. Y. Terada
Journal: Journal of Clinical Oncology (2010)

e12013 Background: Cancer occurs in approximately 0.1% of pregnant women and is the second leading cause of mortality in women of reproductive age. Yet, relatively little is known regarding how pregnancy affects cancer outcome. The current study was undertaken to compare site specific cancer related maternal mortality to cancer mortality in non-pregnant reproductive age women for the State of Hawaii. Methods: Death certificates for all women that died from cancer during pregnancy and post-partum were obtained from the State Department of Health for the period 1991-2007. Two reporting changes occurred beginning in 2006. Previous to 2006 pregnancy was only reported on the death certificate following live births; beginning in 2006 it was reported for all pregnancies. Also beginning in 2006 the reporting window for recording pregnancy on the death certificate changed from 42 to 365 days. There were 28 women during this 16 year period that had cancer listed as a cause of death either during or following pregnancy. Information regarding the primary site was abstracted and compared to cancer mortality in the Hawaii State Tumor Registry for all women age 17-45 for this same time period. Site specific cancer mortality was then compared between pregnant women and non-pregnant women. The mortality odds ratios were compared using the Mantel-Haenszel procedure. Results: Maternal mortality due to leukemia (p = 0.005) and brain malignancies (p = 0.011) were significantly increased compared to the non-pregnant population. Maternal mortality due to malignancies of the female genital tract were significantly lower (p = 0.029). There was no significant difference in mortality for all other primary sites. Conclusions: There are significant differences in site specific cancer mortality in women who are or have recently been pregnant. The risk is significantly increased for hematologic and brain malignancies. Mortality due to malignancies of the female genital tract, however, is significantly reduced. Enhanced reporting of pregnancy associated mortality beginning in 2006 will hopefully provide additional data and better insight into this critically important issue. No significant financial relationships to disclose.
TCT-299 Adenosine Versus Regadenoson In Assessing Fractional Flow Reserve, A Meta Analysis
Authors: Muhammad S. Azzouz, Alok Saurav, Mohsin Salih, Toufik Mahfood Haddad, Mohamed Ayan, Aiman Smer, Abhilash Akinapelli, Saurabh Aggarwal, Manu Kaushik
Journal: Journal of the American College of Cardiology (2015)
TCT-436 Percutaneous removal using Perclose ProGlide closure devices versus surgical removal as weaning strategy after percutaneous cannulation for venoarterial Extracorporeal Membrane Oxygenation
Authors: Ji-won Hwang, Jeong Hoon Yang, A Young Lim, Hye Bin Gwag, Kyu Tae Park, Seung-Hyuk Choi, Joo-Yong Hahn, Young Bin Song, Jin-Ho Choi, Sang Hoon Lee, Hyeon-Cheol Gwon
Journal: Journal of the American College of Cardiology (2015)
Leukemia-Initiating Cells Are Frequent in Very High Risk Childhood Acute Lymphoblastic Leukemia and Give Rise to Relatively Stable Phenotypes in Immunodeficient Mice.
Authors: Maike Schmitz, Paulina Mirkowska, Petra Breithaupt, Barbara Meissner, Gunnar Cario, Andre Schrauder, Felix Niggli, Martin Schrappe, Martin Stanulla, Beat Bornhauser, Jean-Pierre Bourquin
Journal: Blood (2009)
Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations
Authors: Christoph Heuck, Shweta S. Chavan, Caleb K. Stein, Ruslana Tytarenko, Niels Weinhold, Siraj Ali, Vincent A. Miller, Sharmilan Thanendrarajan, Carolina Schinke, Meera Mohan, Jeffery Sawyer, Erich Allen Peterson, Michael Bauer, Timothy C. Ashby, Donald Johann, Frits van Rhee, Sarah Waheed, Maurizio Zangari, Faith E Davies, Bart Barlogie, Gareth J Morgan
Journal: Blood (2015)
Multitracer Molecular Imaging of Paget Disease Targeting Bone Remodeling, Fatty Acid Metabolism, and PSMA Expression on PET/CT
Authors: Thorsten Derlin, Desiree Weiberg, Jan M. Sohns
Journal: Clinical Nuclear Medicine (2016)

Paget disease is a chronic disorder resulting in enlarged and misshapen bones, and is caused by disorganized bone remodeling. We present the case of an 85-year-old man with prostatic adenocarcinoma and known Paget disease of the right iliac bone who underwent 68Ga–prostate-specific membrane antigen ligand, 11C-acetate, and 18F-fluoride PET/CT for restaging of cancer. On all PET scans, increased tracer accumulation was observed in Paget disease of bone. Besides that Paget disease may mimic metastases on PET/CT using various radiotracers, including 68Ga–prostate-specific membrane antigen ligands and 11C-acetate, this case highlights the potential of multiparametric disease characterization on PET.
Endoscopic ultrasound-guided transmural gallbladder drainage with a lumen-apposing metal stent using an electrocautery enhanced delivery system
Authors: Nikhil Kumta, Marina Lordello Passos, Gustavo Rodela Silva, Aleksey Novikov, Michel Kahaleh
Journal: Endoscopy (2016)

A 77-year-old woman with multiple co-morbidities was referred for symptomatic chronic calculous cholecystitis. She was not a surgical candidate for cholecystectomy and refused percutaneous gallbladder drainage. Endoscopic ultrasound (EUS)-guided transmural gallbladder drainage with a lumen-apposing metal stent (LAMS) using an electrocautery enhanced delivery system was performed ([Video 1]).
PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study
Authors: Maria Bruzelius, Maria Jesus Iglesias, Mun-Gwan Hong, Laura Sanchez-Rivera, Beata Gyorgy, Juan Carlos Souto, Mattias Frånberg, Claudia Fredolini, Rona J. Strawbridge, Margareta Holmström, Anders Hamsten, Mathias Uhlén, Angela Silveira, Jose Manuel Soria, David M. Smadja, Lynn M. Butler, Jochen M. Schwenk, Pierre-Emmanuel Morange, David-Alexandre Trégouët, Jacob Odeberg
Journal: Blood (2016)
TCT-408 De Novo Small Vessel Coronary Disease: To Stent Or Not To Stent? Can Drug Coated Balloon Be A Safe And Effective Alternative To Modern Drug Eluting Stent?
Authors: Dasdo A. Sinaga, Alyssa S. Sim, Hee Hwa Ho, Fahim Haider Jafary, Jason Loh, Yau Wei Ooi, Julian Tan, Paul Ong
Journal: Journal of the American College of Cardiology (2015)
Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
Authors: Rebecca L. Kusko, John F. Brothers, John Tedrow, Kusum Pandit, Luai Huleihel, Catalina Perdomo, Gang Liu, Brenda Juan-Guardela, Daniel Kass, Sherry Zhang, Marc Lenburg, Fernando Martinez, John Quackenbush, Frank Sciurba, Andrew Limper, Mark Geraci, Ivana Yang, David A. Schwartz, Jennifer Beane, Avrum Spira, Naftali Kaminski
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Despite shared environmental exposures, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease are usually studied in isolation, and the presence of shared molecular mechanisms is unknown.We applied an integrative genomic approach to identify convergent transcriptomic pathways in emphysema and IPF.We defined the transcriptional repertoire of chronic obstructive pulmonary disease, IPF, or normal histology lungs using RNA-seq (n = 87).Genes increased in both emphysema and IPF relative to control were enriched for the p53/hypoxia pathway, a finding confirmed in an independent cohort using both gene expression arrays and the nCounter Analysis System (n = 193). Immunohistochemistry confirmed overexpression of HIF1A, MDM2, and NFKBIB members of this pathway in tissues from patients with emphysema or IPF. Using reads aligned across splice junctions, we determined that alternative splicing of p53/hypoxia pathway-associated molecules NUMB and PDGFA occurred more frequently in IPF or emphysema compared with control and validated these findings by quantitative polymerase chain reaction and the nCounter Analysis System on an independent sample set (n = 193). Finally, by integrating parallel microRNA and mRNA-Seq data on the same samples, we identified MIR96 as a key novel regulatory hub in the p53/hypoxia gene-expression network and confirmed that modulation of MIR96 in vitro recapitulates the disease-associated gene-expression network.Our results suggest convergent transcriptional regulatory hubs in diseases as varied phenotypically as chronic obstructive pulmonary disease and IPF and suggest that these hubs may represent shared key responses of the lung to environmental stresses.
Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,
Authors: Jesús F. San-Miguel, Vânia Tietsche de Moraes Hungria, Sung-Soo Yoon, Wieslaw Wiktor-Jedrzejczak, Ashraf Elghandour, Noppadol Siritanaratkul, Meletios Athanasios Dimopoulos, Paolo Corradini, Thanyaphong Na Nakorn, Tatiana Shelekhova, Andreas Günther, Kwee Yong, Robert Schlossman, Monika Wroclawska-Swacha, Hans-Jochen Weber, Priscille Bourquelot, Jian Hou, Hermann Einsele, Jae Hoon Lee, Philippe Moreau, Sagar Lonial, Paul G. Richardson
Journal: Blood (2011)
TCT-453 Four Years Clinical Outcomes of Overlapping Everolimus-Eluting Stents compared with Sirolimus-Eluting Stents
Authors: Dong-Bin Kim, Sung-Ho Her, Pum Joon Kim, Chul Soo Park, Jong Min Lee, Kiyuk Chang, Hee-Yeol Kim, Ki Dong Yoo, Doo Soo Jeon, Wook Sung Chung, Ki-Bae Seung
Journal: Journal of the American College of Cardiology (2015)
Analysis of Bleeding Phenotype of Severe Hemophilia a Carriers and Comparation with a Working Population Group. Impact on Quality of Life
Authors: María Eva Mingot-Castellano, María Jose Ariza-Corbo, Álvaro Amo Vázquez de la Torre, María Inmaculada Alonso-Calderón, Pedro Valdivielso, Ana Isabel Heiniger-Mazo, Miguel Angel Sánchez-Chaparro
Journal: Blood (2014)
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).
Authors: Bernardo Leon Rapoport, Lee Steven Schwartzberg, Martin Robert Chasen, Daniel Powers, Sujata Arora, Rudolph M. Navari, Ian D. Schnadig
Journal: Journal of Clinical Oncology (2015)

210 Background: The long-acting neurokinin-1 receptor antagonist (NK-1 RA) rolapitant has demonstrated efficacy for CINV prevention in patients receiving HEC and MEC during Cycle 1. The efficacy and safety of rolapitant was examined during subsequent cycles 2–6 in a pooled analysis. Methods: In 4 double-blind, active-controlled studies, patients were randomized to oral rolapitant 180 mg or placebo 1–2 hours before chemotherapy. All patients received active control: 5HT 3 receptor antagonist + oral dexamethasone. Patients completing Cycle 1 could receive the same anti-emetic treatment in subsequent cycles. On Days 6-8 of subsequent cycles, patients self-reported the incidence of emesis, or of nausea interfering with normal daily life following Day 1 of chemotherapy. Results: A greater proportion of patients on rolapitant than on active control reported no emesis or interfering nausea separately for each subsequent cycle. Results of individual studies and pooled analysis are shown in the Table. During cycles 2-6, the incidence of treatment-related adverse events (AEs) was similar for rolapitant (5.5%) and control (6.8%). The most common treatment-related AEs were similar in both arms: constipation (rolapitant: 1.2%; control: 0.8%) and fatigue (rolapitant: 1.3%; control: 1.8%). Conclusions: Rolapitant was superior to active control in reducing CINV when administered over multiple cycles of moderately or highly emetogenic chemotherapy, with no increase in toxicity. Clinical trial information: NCT00394966 - NCT01500213 - NCT01500226 - NCT01499849. [Table: see text]
Feasibility of a Stem Cell Gene Therapy Approach with Nonmyeloablative Conditioning in Patients with HIV-1 Infection.
Authors: Gian-Paolo Rizzardi, Silvia Nozza, Lucia Turchetto, Alexandre Harari, Giuseppe Tambussi, Monica Salomoni, Fulvio Crippa, Vega Rusconi, Salvatore Toma, Giuseppe Pantaleo, Adriano Lazzarin, Claudio Bordignon
Journal: Blood (2004)
The Tyrosine Kinase src Is Highly Activated in AML and Plays a Crucial Role in Leukemic Cell Proliferation.
Authors: Gunter Schuch, Ellen Schafer, Katharina Eggert, Sonja Loges, Manfred Jucker, Dieter K. Hossfeld, Carsten Bokemeyer, Walter Fiedler
Journal: Blood (2005)
BP-2-047, a Novel Small-Molecule Inhibitor of Stat3 Is Active in Myeloma Pre-Clinical Models: Rationale for Treatment of Stat3-Dependent Multiple Myeloma
Authors: Victor Hugo Jimenez-Zepeda, Brent DG Page, Li Zhia Hua, Ellen Wei, Leif Bergsagel, Patrick T Gunning, Suzanne Trudel
Journal: Blood (2012)
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.
Authors: Monica Bocchia, Marzia Defina, Micaela Ippoliti, Marilina Amabile, Massimo Breccia, Francesco Iuliano, Marco Vignetti, Gabriele Gugliotta, Antonella Russo Rossi, Giuliana Alimena, Lara Aprile, Gianluca Gaidano, Paolo Nicoli, Malgorzata Monika Trawinska, Renato Bassan, Diamante Turri, Laura Cannella, Luigia Luciano, Alessandro Gozzetti, Michela Rondoni, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Francesco Lauria
Journal: Blood (2009)
TCT-189 The Use of Mechanical Circulatory Support Devices during TAVR: A Single Center Experience with Long Term Follow-up
Authors: Vikas Singh, Rodrigo Mendirichaga, Abdulla Damluji, Conrad Macon, Mohamad Kabach, Magdalena Murman, Donald Williams, Eduardo de Marchena, Claudia A. Martinez, Carlos Alfonso, Mauro Moscucci, Alan W. Heldman, Mauricio G. Cohen, William W. O'Neill
Journal: Journal of the American College of Cardiology (2015)
Germline Activating JAK2 V617I Mutation in a Family with Hereditary Thrombocytosis
Authors: Adam J. Mead, Michelle Rugless, Petter Woll, Ruth Clifford, Debbie Atkinson, Simon Moule, Nicola Bienz, James S. Wainscoat, Paresh Vyas, Shirley Henderson, Sten Eirik W Jacobsen, Anna Schuh
Journal: Blood (2011)
GW27-e1248 Blockage of HIF-1a/Notch1 signaling attenuates c-Kit+ bone marrow mesenchymal stem cells-contributed recovery of cardiac function following myocardial infarction
Authors: Yanping Ha, Zhenliang Wang, Hong Lei, Keke Wang, Yanan Jia, Zhihua Shen, Rujia Li, Junli Guo, Wei Jie
Journal: Journal of the American College of Cardiology (2016)
mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies
Authors: Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Martin E. Fernandez-Zapico, Scott H. Kaufmann
Journal: Blood (2015)
Phase I study of EMD 525797 (DI17E6), an antibody targeting ανβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with <i>k-ras</i> wild-type metastatic colorectal cancer.
Authors: Elena Elez, Ilona Kocáková, Thomas Hoehler, Uwe Marc Martens, Carsten Bokemeyer, Eric Van Cutsem, Robert J Fram, Laurence Bernard, Josep Tabernero
Journal: Journal of Clinical Oncology (2012)

3539 Background: EMD 525797 is a humanized monoclonal antibody that specifically targets all αν integrins, including ανβ1, ανβ3, ανβ5, ανβ6, and ανβ8. In colorectal cancer (CRC), ανβ3 is highly expressed on tumor-associated vessels, and ανβ5 is strongly expressed on tumor cells, vessels, and stromal cells. Overexpression of ανβ6 is associated with a significant reduction in median overall survival. Methods: Safety, tolerability, and anti-tumor activity of escalating doses of EMD525797 in combination with irinotecan and cetuximab were assessed in patients (pts) with metastatic CRC who had failed first-line fluoropyrimidine/oxaliplatin-containing chemotherapy. Pts received IV infusions over 1 hour of 250, 500, 750, and 1,000 mg EMD 525797 every 2 weeks in combination with irinotecan at 180 mg/m 2 IV every 2 weeks and cetuximab at 400 mg/m 2 on Cycle 1, Day 1 and then 250 mg/m 2 IV weekly. A standard 3+3 trial design was used. Three pts were enrolled at each dose level and if no dose limiting toxicities (DLTs) were observed, pts were enrolled at the next dose level. An additional 3 pts were added if 1 of the initial 3 pts in the cohort experienced a DLT. Results: A total of 16 pts received treatment.No DLTs were observed at any dose of EMD 525797 in combination with irinotecan and cetuximab. Serious adverse events related to EMD 525797 included Grade 3 hypokalemia and tachyarrhythmia. Dosing was well tolerated over treatment intervals as long as 18 months. Objective responses included 1 partial response (PR) at 250 mg; 1 complete response and 1 PR at 750 mg; and 2 PRs at 1,000 mg. Two pts had prolonged stable disease lasting longer than 11 weeks at 750 mg. Anti-tumor activity was observed in pts who had failed anti-VEGF therapy in combination with first-line chemotherapy. Conclusions: The combination of EMD 525797 with irinotecan and cetuximab was well tolerated and has anti-tumor activity. Further evaluation of this regimen is warranted and is underway in an open-label, randomized phase II study of two doses of EMD 525797 (500 and 1,000 mg) combined with irinotecan and cetuximab that are compared with standard irinotecan and cetuximab.
Is HLA-Haploidentical Hematopoietic Stem Cell Transplantation a Valid Alternative Option for Patients with Combined Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia (AA/PNH Syndrome)?
Authors: Feng Chen, Wu Depei, Xiaowen Tang, Miao Miao, Chengcheng Fu, Huiying Qiu, Shengli Xue, Xiao Ma, Zhengming Jin
Journal: Blood (2015)
An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59–8862) in patients with taxane-resistant non-small cell lung cancer
Authors: J. S. Gurtler, J. Von Pawel, C. H. Spiridonidis, F. Grossi, J. L. Larriba, M. Moscovici, E. Markovitz, D. Voliotis, M. Gottfried
Journal: Journal of Clinical Oncology (2004)

7136 Background: Ortataxel is a novel second-generation taxane, with potent growth inhibitory activity against human cell lines that express P-glycoprotein 170. Compared to paclitaxel and docetaxel, it is 20–30 times more potent as a growth inhibitory agent against human breast and colon tumor cell lines expressing P-gp 170. Ortataxel is also active in NSCL tumor xenografts. Based on these preclinical and additional phase I data, this phase II study was initiated to assess the safety and efficacy (response rate) of Ortataxel in patients (pts) with taxane-resistant NSCLC. Methods: Ortataxel was administered IV over 60 min every 3 wks at a dose of 75 mg/m2. Pts with taxane resistant NSCLC, with at least one measurable lesion, ECOG score 0, 1, or 2, adequate hematology and biochemistry, and no more than 2 prior anticancer chemotherapy regimens were eligible. Taxane resistance was defined as PD during treatment (Rx) or within 6 months of Rx with a prior taxane. The protocol was amended to include pts with brain metastases (BM). Results: 98 pts were enrolled. Clean data is available for the first 65 pts: 25 F, 40M; median age 60 (38 - 77); ECOG 0/1/2 - 19/37/9 respectively; prior chemo regimens: 0 (0 pt.), 1 (29 pts.), 2 (34 pts.), 3 (2 pts. received Iressa as 3rd regimen). Median number of cycles administered: 2 (1–11). 89% (58) pts received >90% planned dose intensity. Common drug related non-hematological toxicities included: fatigue 25(38%), nausea 19(29%), myalgia 18(27%), sensory neuropathy 17(26%), vomiting 15(23%), constipation 14(21%), diarrhea 11(17%), arthralgia 10(15%), alopecia 9(13%), stomatitis/pharyngitis 9(13%). Hematologic toxicities seen: G 3–4 neutropenia 49%, G3–4 anemia 7%. 4(6%) pts (without BM) had a PR, 25(38%) pts had SD, 31(48%) pts had PD. 5 pts were not evaluable (missing post baseline evaluations due to consent withdrawal in 2 pts and AE's in 3 pts). Conclusion: Four investigator-confirmed partial responses to Ortataxel were documented in this trial so far. An independent review is underway. The study continues to enroll only pts with BM in order to assess the drug in this subset of patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Healthcare; Pharma-Clinical Ltd.
GW27-e1127 GLP-1 analog liraglutide attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin-induced diabetic rats
Authors: Li Cairong, Hui Yu, Shou-yi Gan, Xin-yuan Zhao, Ling-yong Zeng, Hong-xia Huang, Fei Cai
Journal: Journal of the American College of Cardiology (2016)